Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1801 Injection plus rabies vaccine in suspected rabies virus category III exposure
CTR20222502Phase 3Completed
- Sponsor
- Zhixiang (Shanghai) Pharmaceutical Technology Co., Ltd.
- Start
- Sep 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of silevimig in rabies (2 arms), sponsored by Zhixiang (Shanghai) Pharmaceutical Technology Co., Ltd. Primary endpoints: RVNA level at day 7 after dosing, RVNA positivity rate at day 14 after dosing and 1 more. Started Sep 2022; status: completed.
02
Drugs
silevimig
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20222502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222502.